KMT2A and leukemia: This synergistic inhibition was confirmed in human and mouse models of FLT3mut leukemias with NPM1 (MI-503, VTP-50469 and Ponatinib/Gilteritinib) and MLL-r (MI-503, VTP-50469 and Quizartinib) with increased antileukemic efficacy determined by the combination of the inhibitors compared to single drug treatment.